EFOI
Energy Focus, Inc.
There isn't enough reported data to score EFOI yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
EFOI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Healthy | |
| Unavailable |
EFOI's revenue and cash flow are currently healthy, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EFOI PE Valuation
EFOI has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
EFOI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect EFOI's losses to grow, with revenue growing.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EFOI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.03 |
| Q2 2026 | -$0.25 | -$0.05 |
| Q1 2026 | -$0.15 | +$0.13 |
| Q4 2025 | -$0.18 | +$0.14 |
| Q3 2025 | -$0.17 | +$0.65 |
| Q2 2025 | -$0.20 | +$0.83 |
| Q1 2025 | -$0.28 | +$1.05 |
| Q4 2024 | -$0.32 | +$1.48 |
EFOI has the edge over LCID on earnings, with more consistent year-over-year improvement.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
EFOI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.8M | +481% |
| Q2 2026 | $3.7M | +228% |
| Q1 2026 | $949K | +54% |
| Q4 2025 | $975K | -24% |
| Q3 2025 | $826K | -31% |
| Q2 2025 | $1.1M | -26% |
| Q1 2025 | $616K | -26% |
| Q4 2024 | $1.3M | -47% |
EFOI's revenue is recovering but still below its 2020 peak: $5M last quarter, up 481% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +32 points |
| Q2 2026 | -23% | -3.5 points |
| Q1 2026 | -15% | +29 points |
| Q4 2025 | -37% | -14 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -20% | +16 points |
| Q1 2025 | -44% | +28 points |
| Q4 2024 | -23% | +9.4 points |
EFOI has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over EFOI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
EFOI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +$2.3M |
| Q2 2026 | -$819K | -$604K |
| Q1 2026 | $69K | +$346K |
| Q4 2025 | -$862K | -$608K |
| Q3 2025 | -$104K | +$182K |
| Q2 2025 | -$215K | +$503K |
| Q1 2025 | -$277K | -$219K |
| Q4 2024 | -$254K | -$143K |
EFOI has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
EFOI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +67K shares |
| 1 year | +14% | +784K shares |
| 3 years | +131% | +3.6M shares |
| 5 years | +963% | +5.8M shares |
| Available history | +1350% | +6M shares |
EFOI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
EFOI Net Leverage
EFOI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EFOI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.4 | Neutral |
| Stochastic | 76.9 | Neutral |
EFOI's weekly RSI is 68 (neutral) and its Stochastic is 77 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
EFOI PE vs Consumer Cyclical Sector
EFOI has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
EFOI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 34% above |
| 20 week MA | $3.10 | 45% above |
| 50 week MA | $2.90 | 55% above |
| 100 week MA | $2.47 | 82% above |
| 200 week MA | $2.25 | 100% above |
EFOI has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
EFOI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.1 | $29.4 | +83% |
| 2021 | $29.4 | $28.1 | -4.3% |
| 2022 | $28.1 | $2.10 | -93% |
| 2023 | $2.10 | $1.51 | -28% |
| 2024 | $1.51 | $1.25 | -17% |
| 2025 | $1.25 | $2.25 | +80% |
| 2026 YTD | $2.25 | $4.50 | +100% |
EFOI has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.